Biomea Fusion Inc
Health Care · USD
Price
$1.87
Cap
$134M
Earnings
1/2 beat
30d Trend
+1%
Lower half of range — may offer entry value
Target range: $5 – $18 (consensus: $9.83)
Consensus: Strong Buy
Earnings history
Q4 2025
BEAT
0.27 vs -0.23
Q3 2025
MISS
-0.27 vs -0.26
Key macro factors
Regulatory Approvals & Clinical Trial Success: The approval of its drug candidates (icovamenib and BMF-650) in clinical trials and subsequent regulatory approvals are critical for commercialization and revenue generation.
Competition in Diabetes and Obesity Markets: The highly competitive landscape of diabetes and obesity treatments, including existing therapies and new GLP-1 based drugs, poses a challenge for market penetration.
Healthcare Policy & Reimbursement Trends: Changes in healthcare policy, drug pricing regulations, and reimbursement frameworks for novel metabolic disease treatments can significantly impact the company's future profitability and market access.
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases, including diabetes and obesity.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.